Jesús Fuentes Antrás, Medical Oncologist and Clinical Investigator at NEXT Oncology, Quirónsalud Madrid University Hospital, shared a post on LinkedIn:
“ASCO 2026 has brought a continued shift toward more refined, biologically informed oncology drug development.
From daraxonrasib’s momentum to multispecific antibodies, dual adc payloads, and increasingly sophisticated cell therapy platforms, the technical progress felt incremental rather than transformative – but meaningful nonetheless.
A great few days of discussions and reconnecting with colleagues and old friends from across the field!”
Other articles featuring Jesús Fuentes Antrás on OncoDaily.
